BioNTech, DualityBio say DYNASTY-Breast02 Phase 3 trial met primary endpoint with modest PFS improvement for trastuzumab pamirtecan

BioNTech and DualityBio said the Phase 3 DYNASTY-Breast02 trial met its primary endpoint, showing a statistically significant yet modest progression-free survival improvement for trastuzumab pamirtecan, with a higher ILD rate and overall survival data not yet mature.

Detected & updated continuously · Source: Nebula